Attorney's Docket No.: 10223-006001

Applicant: Lars Hellman Serial No.: 09/401,636

Filed: September 22, 1999

Page: 2

(ORO-trunc) (SEQ ID NO:5); opossum CH2—mouse CH3—opossum CH4 (OMO) (SEQ ID NO:6); opossum CH2—CH3—CH4 (OOO) (SEQ ID NO:3); platypus CH2—CH3—CH4 (PPP) (SEQ ID NO:7); opossum CH2—human CH3—opossum CH4 (OHO) (SEQ ID NO:8); opossum CH2—pig CH3—opossum CH4 (OPO) (SEQ ID NO:9); and opossum CH2—dog CH3—opossum CH4 (ODO) (SEQ ID NO:10). The arrows indicate domain borders

In the claims:

Please cancel claims 41-54 without prejudice.

Please amend claims 25, 27, 28, 33, 35, 36, and 38 as follows:

- CH3 domain and one or more non-self IgE domains, wherein at least one of said non-self IgE domains comprises an IgE sequence present in a non-placental mammal, wherein said immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal, and wherein said immunogenic polypeptide lacks a CH1 domain of IgE.
- 27. (Amended Twice) The immunogenic polypeptide of claim 26, wherein the sequence of said immunogenic polypeptide is as set forth in SEQ ID NO:4.
- 28. (Amended Once) The immunogenic polypeptide of claim 25, wherein said non-placental mammal is selected from the group consisting of opossum, platypus, koala, kangaroo, wallaby, and wombat.
- 33. (Amended Twice) An immunogenic polypeptide, consisting essentially of one or more non-self IgE domains, and at least an N-terminal half of a self IgE CH3 domain, wherein at least one of said non-self IgE domains comprises an IgE sequence present in a non-placental mammal, and wherein said immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal.

Attorney's Docket No.: 10223-006001

Applicant: Lars Hellman Serial No.: 09/401,636

Filed: September 22, 1999

Page: 3

35. (Amended Twice) The immunogenic polypeptide of claim 34, wherein the sequence of said immunogenic polypeptide is as set forth in SEQ ID NO:4.

Mammal is selected from the group consisting of opossum, platypus, koala, kangaroo, wallaby, and wombat.

38. (Amended Twice) The immunogenic polypeptide of claim 33, wherein one of said non-self IgE domains is an IgE CH2 domain, wherein one of said non-self IgE domains is an IgE CH4 domain, and wherein said at least an N-terminal half of a self IgE CH3 domain is located between said IgE CH2 domain and said IgE CH4 domain [--]